Literature DB >> 22633616

Benzodiazepine-induced spatial learning deficits in rats are regulated by the degree of modulation of α1 GABA(A) receptors.

Srđan Joksimović1, Jovana Divljaković, Michael L Van Linn, Zdravko Varagic, Gordana Brajković, Marija M Milinković, Wenyuan Yin, Tamara Timić, Werner Sieghart, James M Cook, Miroslav M Savić.   

Abstract

Despite significant advances in understanding the role of benzodiazepine (BZ)-sensitive populations of GABAA receptors, containing the α1, α2, α3 or α5 subunit, factual substrates of BZ-induced learning and memory deficits are not yet fully elucidated. It was shown that α1-subunit affinity-selective antagonist β-CCt almost completely abolished spatial learning deficits induced by diazepam (DZP) in the Morris water maze. We examined a novel, highly (105 fold) α1-subunit selective ligand-WYS8 (0.2, 1 and 10 mg/kg), on its own and in combination with the non-selective agonist DZP (2 mg/kg) or β-CCt (5 mg/kg) in the water maze in rats. The in vitro efficacy study revealed that WYS8 acts as α1-subtype selective weak partial positive modulator (40% potentiation at 100nM). Measurement of concentrations of WYS8 and DZP in rat serum and brain tissues suggested that they did not substantially cross-influence the respective disposition. In the water maze, DZP impaired spatial learning (acquisition trials) and memory (probe trial). WYS8 caused no effect per se, did not affect the overall influence of DZP on the water-maze performance and was devoid of any activity in this task when combined with β-CCt. Nonetheless, an additional analysis of the latency to reach the platform and the total distance swam suggested that WYS8 addition attenuated the run-down of the spatial impairment induced by DZP at the end of acquisition trials. These results demonstrate a clear difference in the influence of an α1 subtype-selective antagonist and a partial agonist on the effects of DZP on the water-maze acquisition.
Copyright © 2012 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633616      PMCID: PMC3448846          DOI: 10.1016/j.euroneuro.2012.05.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  31 in total

Review 1.  Structure, pharmacology, and function of GABAA receptor subtypes.

Authors:  Werner Sieghart
Journal:  Adv Pharmacol       Date:  2006

Review 2.  GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.

Authors:  John R Atack
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 3.  Testing the NMDA, long-term potentiation, and cholinergic hypotheses of spatial learning.

Authors:  D P Cain
Journal:  Neurosci Biobehav Rev       Date:  1998-03       Impact factor: 8.989

Review 4.  Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal.

Authors:  A N Bateson
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

Review 5.  Applications of the Morris water maze in the study of learning and memory.

Authors:  R D'Hooge; P P De Deyn
Journal:  Brain Res Brain Res Rev       Date:  2001-08

6.  The point mutation gamma 2F77I changes the potency and efficacy of benzodiazepine site ligands in different GABAA receptor subtypes.

Authors:  Joachim Ramerstorfer; Roman Furtmüller; Elisabeth Vogel; Sigismund Huck; Werner Sieghart
Journal:  Eur J Pharmacol       Date:  2010-03-19       Impact factor: 4.432

7.  Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417.

Authors:  P Scott-Stevens; J R Atack; B Sohal; P Worboys
Journal:  Biopharm Drug Dispos       Date:  2005-01       Impact factor: 1.627

8.  Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors.

Authors:  Valerie B Caraiscos; Erin M Elliott; Kong E You-Ten; Victor Y Cheng; Delia Belelli; J Glen Newell; Michael F Jackson; Jeremy J Lambert; Thomas W Rosahl; Keith A Wafford; John F MacDonald; Beverley A Orser
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

Review 9.  Current use of benzodiazepines in anxiety disorders.

Authors:  Jean-Marc Cloos; Valérie Ferreira
Journal:  Curr Opin Psychiatry       Date:  2009-01       Impact factor: 4.741

10.  Rapid down-regulation of [3H]zolpidem binding to rat brain benzodiazepine receptors during flurazepam treatment.

Authors:  Y Wu; H C Rosenberg; T H Chiu
Journal:  Eur J Pharmacol       Date:  1995-05-15       Impact factor: 4.432

View more
  5 in total

1.  Insights into functional pharmacology of α₁ GABA(A) receptors: how much does partial activation at the benzodiazepine site matter?

Authors:  Srđan Joksimović; Zdravko Varagic; Jovana Kovačević; Michael Van Linn; Marija Milić; Sundari Rallapalli; Tamara Timić; Werner Sieghart; James M Cook; Miroslav M Savić
Journal:  Psychopharmacology (Berl)       Date:  2013-05-18       Impact factor: 4.530

2.  Differential impacts on multiple forms of spatial and contextual memory in diazepam binding inhibitor knockout mice.

Authors:  Ammar L Ujjainwala; Connor D Courtney; Natalia M Wojnowski; Justin S Rhodes; Catherine A Christian
Journal:  J Neurosci Res       Date:  2019-01-25       Impact factor: 4.164

3.  Impaired Cognitive Function and Hippocampal Changes Following Chronic Diazepam Treatment in Middle-Aged Mice.

Authors:  Tomonori Furukawa; Yoshikazu Nikaido; Shuji Shimoyama; Nozomu Masuyama; Ayaka Notoya; Shinya Ueno
Journal:  Front Aging Neurosci       Date:  2021-11-26       Impact factor: 5.750

4.  Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia.

Authors:  Miren Ettcheto; Jordi Olloquequi; Elena Sánchez-López; Oriol Busquets; Amanda Cano; Patricia Regina Manzine; Carlos Beas-Zarate; Rubén D Castro-Torres; Maria Luisa García; Mónica Bulló; Carme Auladell; Jaume Folch; Antonio Camins
Journal:  Front Aging Neurosci       Date:  2020-01-08       Impact factor: 5.750

5.  Association Between Z Drugs Use and Risk of Cognitive Impairment in Middle-Aged and Older Patients With Chronic Insomnia.

Authors:  Fang Guo; Li Yi; Wei Zhang; Zhi-Jie Bian; Yong-Bo Zhang
Journal:  Front Hum Neurosci       Date:  2021-12-09       Impact factor: 3.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.